Biosimilars Showing Accelerated Uptick in Japan, Doctor Fee Incentive as Tailwind

Despite people shunning hospital visits amid the COVID-19 pandemic, Japan is seeing an accelerated penetration of biosimilars such as those of Forteo (teriparatide) and Enbrel (etanercept) on the back of a new reimbursement fee incentive rolled out in April. In...read more